Physician profile
John C Tanner
NPI 1952337990
$29,097.24
in general payments reported to CMS, 2019-2025
18 companies · $6,983 in 2025
The $6,983 reported for 2025 was more than what 94% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,194 · 2020: $196 · 2021: $146 · 2022: $49.28 · 2023: $8,473 · 2024: $10K · 2025: $6,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Food and Beverage: $2,792 · Travel and Lodging: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $19,995.00 |
| Food and Beverage | $2,792.12 |
| Travel and Lodging | $2,724.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $23,498.95 | 2023-2025 | Brixadi |
| Kaleo, INC. | $1,940.64 | 2019 | |
| Indivior INC. | $1,001.34 | 2019-2025 | Sublocade |
| Abbvie INC. | $704.01 | 2023-2025 | Vraylar |
| Alkermes, INC. | $334.30 | 2019-2025 | Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $327.99 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $225.41 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $206.79 | 2023-2025 | Quviviq, Quviviq |
| Pfizer INC. | $153.87 | 2019-2023 | |
| Abiomed | $149.02 | 2025 | |
| Gilead Sciences, INC. | $128.46 | 2025 | Epclusa |
| Pear Therapeutics (US), INC. | $124.98 | 2021 | |
| Edwards Lifesciences Corporation | $99.80 | 2025 | Sapien 3 Ultra Resilia |
| Orexo US, INC. | $87.97 | 2019-2022 | |
| Amgen INC. | $41.96 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $30.48 | 2025 | Attruby |
| Lundbeck LLC | $20.68 | 2024 | Rexulti |
| Novo Nordisk INC | $20.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.